Abstracts tagged "Chronic pain"

Abstract Number: 0379 • ACR Convergence 2021
Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
Elisabet Lindqvist¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Mats Geijer⁵, Lars Erik Kristensen⁶, Jack Kvistgaard Olsen⁶, Jonas Sagard⁷, Johan Karlsson Wallman⁸ and Elisabeth Mogard¹, ¹Department of Rheumatology, Skane University Hospital, Lund, Sweden, ²Lund University and Skane University Hospital, Lund, Sweden, ³Spenshult Research and Development Centre, Halmstad, Sweden, ⁴Spenshult research and development centre, Vilsharad, Sweden, ⁵University of Gothenburg, Sahlgrenska Academy, Institute of Clinical Sciences, Department of Radiology, Göteborg, Sweden, ⁶Parker Institute, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Department of Rheumatology, Copenhagen, Denmark, ⁷Skåne University Hospital, Lund, Sweden, ⁸Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Chronic widespread pain (CWP) is common in axial spondyloarthritis (axSpA). For ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) patients, no differences were found in…
Abstract Number: 040 • 2020 Pediatric Rheumatology Symposium
Patient-Proxy Agreement on Mental Health and Neuropsychological Symptoms Among Youth with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ³, Nina Thomas ⁴, Kimberly S. Miller ⁴, Jami F. Young ⁴, Pamela Weiss ⁴, David D. Sherry ⁴ and Jeffrey S. Gerber ⁴, ¹Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ²Children's Hospital of Philadelphia, Cherry Hill, ³University of Pennsylvania, Philadelphia, ⁴Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Adolescents with juvenile fibromyalgia syndrome (JFMS) present with a myriad of mental health and neuropsychological symptoms, including dyscognition (“brain fog”); however, patient-proxy agreement on…
Abstract Number: 089 • 2020 Pediatric Rheumatology Symposium
Associations Among Pain, Mood, and Sleep in Children with Rheumatic Conditions
Arionna Rudolph¹, Kathryn Thompson ¹, Aaron Fobian ¹, Matthew Stoll ¹, Peter Weiser ² and Burel Goodin ¹, ¹University of Alabama at Birmingham, Birmingham, ²Birmingham
Background/Purpose: Chronic pain in school-aged children and adolescents is highly prevalent and can be debilitating. Literature suggests that children with musculoskeletal pain are at risk…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 146 • 2020 Pediatric Rheumatology Symposium
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Saumya Joshi¹, Yujuan Zhang ¹, Lori Lyn Price ², Trevor Davis ³ and Raveendhara Bannuru ¹, ¹Tufts Medical Center, Boston, Massachusetts, ²Boston, Massachusetts, ³Norwell, Massachusetts
Background/Purpose: Amplified Musculoskeletal Pain Syndrome (AMPS), a chronic pain syndrome with excessive musculoskeletal pain without a primary organic etiology, has a high prevalence in adolescents.…
Abstract Number: 2721 • 2019 ACR/ARP Annual Meeting
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ², Elizabeth Mendoza ², Kimberly S. Miller ³, Nina H. Thomas ¹, Pamela F. Weiss ¹, David D. Sherry ¹ and Jeffrey Gerber ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital fo Philadelphia, Philadelphia, PA
Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this…
Abstract Number: 2760 • 2019 ACR/ARP Annual Meeting
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Michael Billard ¹, John Todhunter ¹, Margaret Fleming ¹, Tim Warneke¹, Yuhui Qiu ², Nhu Ly ², William Aronstein ² and William Moore ¹, ¹Vizuri Health Sciences, LLC, Columbia, MD, ²CTI Clinical Trial & Consulting, Covington, KY
Background/Purpose: There is considerable unmet medical need for an osteoarthritic knee pain (OAKP) treatment that does not require regular daily use, does not carry gastrointestinal…
Abstract Number: 2766 • 2019 ACR/ARP Annual Meeting
Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment
Dennis Turk ¹, Marco Boeri², Lucy Abraham ³, Brett Hauber ⁴, Joanna Atkinson ³, Andrew Bushmakin ⁵, Joseph Cappelleri ⁵, Leo Russo ⁶, Lars Viktrup ⁷ and David Walsh ⁸, ¹University of Washington, Seattle, ²RTI Health Solutions, Belfast, Northern Ireland, United Kingdom, ³Pfizer, LTD, Surrey, England, United Kingdom, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer, Inc., Collegeville, PA, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom
Background/Purpose: Monoclonal antibodies that inhibit nerve growth factor (NGF-abs) may offer an alternative to current nonsteroidal anti-inflammatory drug (NSAID) and opioid treatments for osteoarthritis (OA)…
Abstract Number: 2929 • 2019 ACR/ARP Annual Meeting
Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
Kristin Wipfler ¹, Teresa Simon², Patricia Katz ³, Frederick Wolfe ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³University of California, San Francisco, san francisco, CA, ⁴FORWARD, The National Databank for Rheumatic Diseases & University of Nebraska Medical Center, Wichita, KS, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results…
Abstract Number: 222 • 2019 ACR/ARP Annual Meeting
Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials
Yujuan Zhang¹ and Chenchen Wang ², ¹Floating Hospital at Tufts Medical Center, Boston, ²Tufts Medical Center, Boston
Background/Purpose: Acupuncture has been widely used for pain relief in adults. Evidence on effects of acupuncture for pediatric chronic musculoskeletal pain is scarce. We have reviewed existing…
Abstract Number: 256 • 2019 ACR/ARP Annual Meeting
Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States
Debbie Ehrmann Feldman¹ and Richard Nahin ², ¹University of Montreal, Montreal, QC, Canada, ²National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
Background/Purpose: Chronic musculoskeletal pain can affect up to 20% of persons under the age of 25 and is a risk factor for persistent chronic musculoskeletal…
Abstract Number: 274 • 2019 ACR/ARP Annual Meeting
Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis
Dina Jones¹, Louise Murphy ², Ranjita Misra ¹, Alison Vargovich ³, Dana Guglielmo ⁴, Maura Robinson ¹, Samantha Shawley-Brzoska ¹, Sijin Wen ¹, Megan Burkart ¹ and Richard Vaglienti ¹, ¹West Virginia University, Morgantown, WV, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³University at Buffalo - SUNY, Buffalo, NY, ⁴Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA
Background/Purpose: In 2016, 1 in 5 US adults reported chronic pain (CP). Osteoarthritis and rheumatoid arthritis are top causes of CP. The Stanford University Chronic…
Abstract Number: 831 • 2019 ACR/ARP Annual Meeting
Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain
Gary Macfarlane¹, Marcus Beasley ¹, Neil Scott ¹, Gordon Prescott ², Paul McNamee ¹, John McBeth ³, Gareth Jones ¹, Neil Basu ⁴, Phil Hannaford ¹, Phil Keeley ⁵ and Karina Lovell ⁶, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Central Lancashire, Preston, United Kingdom, ³Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵University of Huddersfield, Huddersfield, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: Cognitive behaviour therapy (CBT) is effective in the management of fibromyalgia (and its characteristic feature Chronic Widespread Pain (CWP). CBT is recommended in all…
Abstract Number: 1754 • 2019 ACR/ARP Annual Meeting
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Matthew Taylor ¹, Sabrina Gmuca ², Lakshmi Moorthy ³, Alexis Boneparth ⁴ and Daniel Horton³, ¹Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Columbia University Medical Center, New York, NY
Background/Purpose: Chronic musculoskeletal (MSK) pain has been associated with chronic illnesses, including mental disorders, and with high rates of pain medication use, often in referral…
Abstract Number: 2076 • 2019 ACR/ARP Annual Meeting
The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain
Michael Grant¹, Alysia Kwiatkowski ¹ and Najia Shakoor ¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: Pain is the hallmark symptom of many rheumatologic conditions and chronic pain management is a major part of clinical practice in rheumatology. Therefore, as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].